Press Releases

Promore Pharma Interim report January – June 2022

The last clinic visit conducted in Promore Pharma’s phase II study of ensereptide

Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022

Promore Pharma — interim report January-March 2022

Promore Pharma’s Annual Report 2021 and AGM related Documents Published

NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL)

Promore Pharma has reached recruitment goal in clinical trial of ensereptide

Interim report January – December 2021

First patient recruited to Promore Pharma’s clinical trial regarding scarring according to plan

Promore Pharma deregisters warrants

Interim report January – September 2021

Nomination Committee Appointed for the Annual General Meeting 2022 in Promore Pharma

Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention

Promore Pharma announces that scientific article has been published on clinical study results with ropocamptide for venous leg ulcers

Promore Pharma receives delivery of hyaluronic acid from Italian manufacturer Fidia

Interim report January – June 2021

The rights issue is registered and the trading in Paid Subscription Shares ceases

Outcome in Promore Pharma’s rights issue

Promore Pharma publishes prospectus

Promore Pharma informs about the last day of trading to receive subscription rights

Interim report January – March 2021

Report from an extra General Meeting of Promore Pharma AB held on 27 May 2021

Report from the Annual General Meeting of Promore Pharma AB held on 27 May 2021

Notice of Extraordinary General Meeting in Promore Pharma AB (publ)

Promore Pharma AB intends to carry out a fully secured rights issue in order to implement the new strategy

Promore Pharma’s Annual Report 2020 and AGM related Documents Published

Promore Pharma signs agreement on production of hyaluronic acid with Italian manufacturer Fidia

NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL)

Promore Pharma deregisters warrants

Promore Pharma updates its strategy and focuses on scar prevention

Year-end report 2020

Promore Pharma changes Certified Adviser to Erik Penser Bank AB

Interim report January – September 2020

Clarification of outcome in the clinical trial HEAL LL-37

Promore Pharma announces positive results from Phase IIb study of ropocamptide in the treatment of venous leg ulcers

Promore Pharma AB (publ) Interim report January – June 2020

Promore Pharma Appoints Erik Magnusson as Chief Financial Officer

Report from the Annual General Meeting of Promore Pharma AB held on 26 May 2020

Promore Pharma AB (publ) Interim report January – March 2020

Promore Pharma’s Annual Report 2019 Published

Notice of Annual General Meeting in Promore Pharma AB (publ)

Promore Pharma´s CFO leaves the company in 2020

Promore Pharma reached the targeted number of patients completing treatment in the HEAL LL-37 Phase IIb clinical trial

Promore Pharma AB (publ) Year-end report 2019

Promore Pharma has finalized recruitment of patients in HEAL LL-37 early

Promore Pharma’s rights issue completed

Promore Pharma publishes supplementary prospectus in connection with the ongoing rights issue

Promore Pharma AB (publ) Interim report January – September 2019

Promore Pharma publishes prospectus in connection with rights issue

Report from the Extraordinary Shareholders’ Meeting of Promore Pharma AB held on 22 October 2019

Promore Pharma engages ABG Sundal Collier as liquidity provider

Notice of Extraordinary Shareholders’ Meeting in Promore Pharma AB (publ)

Promore Pharma Promore Pharma carries out a rights issue of approximately SEK 75 million, underwritten up to 80 percent, and intends to publish its interim report early

Promore Pharma AB (publ) Interim report January – June 2019

Promore Pharma has recruited half of the patients in HEAL LL-37

Report from the Annual General Meeting of Promore Pharma AB held on 21 May 2019

Promore Pharma AB (publ) Interim report January – March 2019

Notice of Annual General Meeting in Promore Pharma AB (publ)

Promore Pharma AB (publ) Year-end report 2018

Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study

Promore Pharma AB (publ) Interim report January – September 2018

Promore Pharma receives approval for Phase III study with PXL01 in India

Promore Pharma has had a successful meeting with the FDA regarding PXL01

Promore Pharma has enrolled first patient in HEAL LL-37 in Poland

Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland

Interim report January – June 2018

Promore Pharma receives approval for Phase IIb trial with LL-37

Report from the Annual General Meeting of Promore Pharma AB held on 16 May 2018

Promore Pharma AB (publ) Interim report January – March 2018

Promore Pharma Out-licenses PXL01 for Spinal Surgery to PharmaResearch Products Ltd

Promore Pharma 2017 Annual report published

Notice of Annual General Meeting in Promore Pharma AB (publ)

Promore Pharma Regains Rights for PXL01 Manufacturing

Year-end report 2017

Promore Pharma Adjusts Plans for PXL01 in North America

Interim report January – September 2017

Promore Pharma Signs Out-licensing Agreement with Transdermal Therapeutic Technologies for its Peptide DPK-060

Interim report January – June 2017